QLS-111’s novel intraocular pressure-lowering mechanism targeting EVP to be highlighted in an oral presentation and two poster presentations DEDHAM, Mass. — June 23, 2025 — Qlaris Bio, Inc., a clinical‐stage biotechnology company dedicated to developing first‐in‐class therapies for glaucoma, today announced that new data from studies of its lead investigational compound QLS-111 will be presented […]